PITTSBURGH, Feb. 14, 2012 /PRNewswire/ -- Neuro Kinetics, Inc. (NKI) (www.neuro-kinetics.com), manufacturers and marketers of noninvasive medical diagnostic equipment used worldwide for neurophysiologic/ neurotologic testing, said today that it is presenting at the National Institutes of Health's (NIH) Feedback Sessions in Washington D.C. on February 28, 2012.
The Feedback Sessions are an invitation only program funded by the NIH in cooperation with the Larta Institute (www.larta.org) called the SBIR Commercialization Assistance Program (CAP). CAP exposes some of the nation's most promising small life science and healthcare companies and their technologies and business strategies to the investment community, strategic partners and licensees.
NKI, with assistance from NIH and Larta, is presenting to investors, life science professionals and consultants, and corporate development officers at 8:30 Tuesday morning the 28th.
"NKI is honored to be one of only forty companies selected to participate," said Vince Kytka, Director of Operations and Marketing. "This program is a great opportunity for accelerating our path to market."
NKI, poised for exciting growth, has had promising success with its I-Portal® technology to diagnose concussions, and, with the support of NIH's SBIR program, it is progressing in the development of its revolutionary I- Portal® Retinopathy product, a new, non-invasive ophthalmic diagnostic device. Initial data suggests this tool can provide early detection of diabetic retinopathy.
"We are looking forward to this great opportunity to share our progress and potential with such a knowledgeable and influential group," added Howison Schroeder, President and CEO.
Admission to the sessions are limited and by invitation only. If you are interested in attending, please send your contact info to
|SOURCE Neuro Kinetics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved